- Conditions
- Type 2 Diabetes Mellitus, Chronic Kidney Disease
- Interventions
- Fasiglifam, Placebo, Antihyperglycemic therapy
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 7
- States / cities
- Whittier, California • Westminster, Colorado • Tampa, Florida + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Canagliflozin 100 mg, Canagliflozin 300 mg, Antihyperglycemic agent(s), Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 716 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 34
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 31 more
- Conditions
- Tolerance, Side Effect, Glucose Response
- Interventions
- Acarbose Tablets 50mg
- Drug
- Lead sponsor
- AgelessRx
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Proteus Sustained Behavior Change system, Regularly prescribed diabetes medicines (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors)
- Device · Drug
- Lead sponsor
- Proteus Digital Health, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Boston, Massachusetts
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- liraglutide, alpha-glucosidase inhibitors, DPP-4 inhibitors, meglitinides, SGLT-2 inhibitors, sulphonylurea, thiazolidinediones
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,991 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 179
- States / cities
- Birmingham, Alabama • Haleyville, Alabama • Tuscumbia, Alabama + 157 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- LY2963016, Lantus, OAMs
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 759 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 28
- States / cities
- Montgomery, Alabama • Brooksville, Florida • Fort Lauderdale, Florida + 25 more
- Conditions
- Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies), Healthy Subjects (Treated With no Diabetes Therapies)
- Interventions
- exenatide, Other antidiabetic therapies, No diabetes therapy
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- Not listed
- Enrollment
- 363,766 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
- Conditions
- Pompe Disease
- Interventions
- Pyridostigmine Bromide
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 8 Years to 60 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Gainesville, Florida